Supporting cells and their potential roles in cisplatin-induced ototoxicity
Author
dc.contributor.author
Waissbluth, Sofia
Author
dc.contributor.author
Maass Oñate, Juan Cristóbal
Author
dc.contributor.author
Sánchez, Helmuth A.
Author
dc.contributor.author
Martínez, Agustín D.
Admission date
dc.date.accessioned
2023-07-23T21:04:54Z
Available date
dc.date.available
2023-07-23T21:04:54Z
Publication date
dc.date.issued
2022
Cita de ítem
dc.identifier.citation
Front. Neurosci. 16:867034 (2022)
es_ES
Identifier
dc.identifier.other
10.3389/fnins.2022.867034
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/194941
Abstract
dc.description.abstract
Cisplatin is a known ototoxic chemotherapy drug, causing irreversible hearing loss. Evidence has shown that cisplatin causes inner ear damage as a result of adduct formation, a proinflammatory environment and the generation of reactive oxygen species within the inner ear. The main cochlear targets for cisplatin are commonly known to be the outer hair cells, the stria vascularis and the spiral ganglion neurons. Further evidence has shown that certain transporters can mediate cisplatin influx into the inner ear cells including organic cation transporter 2 (OCT2) and the copper transporter Ctr1. However, the expression profiles for these transporters within inner ear cells are not consistent in the literature, and expression of OCT2 and Ctr1 has also been observed in supporting cells. Organ of Corti supporting cells are essential for hair cell activity and survival. Special interest has been devoted to gap junction expression by these cells as certain mutations have been linked to hearing loss. Interestingly, cisplatin appears to affect connexin expression in the inner ear. While investigations regarding cisplatin-induced hearing loss have been focused mainly on the known targets previously mentioned, the role of supporting cells for cisplatin-induced ototoxicity has been overlooked. In this mini review, we discuss the implications of supporting cells expressing OCT2 and Ctr1 as well as the potential role of gap junctions in cisplatin-induced cytotoxicity.
es_ES
Patrocinador
dc.description.sponsorship
Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT-ANID) 11201142
1171240
Fundacion Guillermo Puelma
Fondo Nacional de Investigacion en Salud FONIS-FONDEF SA18I0194
Chilean Millennium Centro Interdisciplinario de Neurociencia de Valparaiso P09-022F
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Frontiers Media
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States